|
| Press Releases |
|
 |
|
| Friday, August 25, 2023 |
|
|
Hua Medicine Announces 2023 Interim Results |
| First-in-class glucokinase activator (GKA) HuaTangNing (dorzagliatin) was approved in China in September 2022. more info >> |
|
| Monday, October 10, 2022 |
|
|
Hua Medicine's Innovative First-In-Class Glucokinase Activator (GKA) HuaTangNing Is Approved, New Type 2 Diabetes Treatment Paradigm to Begin in China |
| Hua Medicine (the "Company", HKEx Stock Code: 2552.HK) today announces that the New Drug Application (NDA) of HuaTangNing (dorzagliatin tablets, HMS5552), a first-in-class glucokinase activator (GKA) developed by the Company has been approved by the National Medical Products Administration (NMPA) of China on October 8th for two indications more info >> |
|
| Tuesday, June 7, 2022 |
|
|
Hua Medicine Announces Dorzagliatin can Restore Glucose Sensitivity and Early Phase Insulin Secretion in T2DM and GCK-MODY Patients at ADA 2022 |
| Hua Medicine (the "Company", stock code: 2552.HK) today announces that several clinical findings were presented on its global first-in-class drug, glucokinase activator (GKA) dorzagliatin, at the 82nd American Diabetes Association (ADA) Annual Scientific Sessions. more info >> |
|
| Friday, May 13, 2022 |
|
|
Hua Medicine Published Two Peer-Reviewed Papers in Nature Medicine, an International Top Medical Journal, on the Results of the Phase III Research of Dorzagliatin, a First-In-Class Investigational Diabetes Drug of Hua Medicine |
| Hua Medicine (the "Company", stock code on the main board of the Hong Kong Stock Exchange: 2552.HK) today announces that, two peer-reviewed papers on the Phase III clinical trial results of dorzagliatin more info >> |
|
| Thursday, March 17, 2022 |
|
|
Hua Medicine Announces 2021 Annual Results |
| Hua Medicine (the "Company", Stock Code: 2552.HK) today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2021 (the "Reporting Period"). The Reporting Period witnessed significant milestones in the commercialization process of dorzagliatin. more info >> |
|
| Sunday, September 26, 2021 |
|
|
Researchers Present Key Research Results on Diabetes Remission of Dorzagliatin |
| Hua Medicine (2552.HK) announced that at the 6th China BioMed Innovation & Investment Conference (CBIIC), Professor Jianhua MA, Director, Department of Endocrinology, Nanjing First Hospital, Standing Member of the Chinese Diabetes Society, as one of the principal researchers presented the results from a clinical study called DREAM, which showed that dorzagliatin, a glucokinase activator and a first-in-class investigational drug of Hua Medicine, may make progress in diabetes remission. more info >> |
|
| Wednesday, September 15, 2021 |
|
|
Hua and Sinopharm Announced Supply Chain Strategic Cooperation |
| On September 13, 2021, Hua Medicine (Shanghai) Ltd. (the "Hua Medicine", Stock Code: 2552.HK) has signed a supply chain strategic cooperation agreement with Sinopharm Group Co., Ltd. (the "Sinopharm", Stock Code: 1099). more info >> |
|
| Thursday, August 19, 2021 |
|
|
Hua Medicine Announces 2021 Interim Results |
| Hua Medicine (the "Company", Stock Code: 2552.HK), today announces the consolidated results of the Company and its subsidiaries for the six months ended June 30, 2021 (the "Reporting Period"). more info >> |
|
| Friday, April 23, 2021 |
|
|
Hua Medicine Announces Acceptance of a New Drug Application for Dorzagliatin in China - First Glucokinase Activator (GKA) Globally |
| Hua Medicine (the "Company", Stock Code: 2552.HK), today announced that the New Drug Application (NDA) for dorzagliatin for the treatment of Type 2 Diabetes (T2D) was accepted by the China National Medical Products Administration (NMPA). more info >> |
|
| Friday, March 19, 2021 |
|
|
Milestone Development Achieved in Clinical Trials and Commercialization, Hua Medicine's Dorzagliatin Readying for NDA Submission |
| Hua Medicine (2552.HK), today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2020 (the "Reporting Period"). more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Fujitsu migrates service operations virtualization platform used by 3,000 companies to Nutanix and introduces migration support services utilizing proven expertise
Oct 10, 2025 23:25 JST
|
|
|
Shares of Golden Leaf International Group Limited Commence Trading on GEM of HKEX Today 
Oct 10, 2025 19:10 HKT/SGT
|
|
|
TripGift(R) Unlocks Glocal Bucket List' Dreams With Launch of New Destination Gift Card SKUs and Marketplaces for Cities, Destinations and Experiences
Oct 10, 2025 15:00 HKT/SGT
|
|
|
IPO Temporarily Slows but Growth Trajectory Unchanged: How Did Hithium Reach Global No. 2 in Six Years?
Oct 10, 2025 14:18 HKT/SGT
|
|
|
Anime Tokyo Station: TV Anime 'SPYxFAMILY' Special Exhibition, New Designs Added for Admission Bonus Illustration Cards
Oct 10, 2025 11:30 JST
|
|
|
TANAKA to Provide Medals Expressing Every Runner's Trail through Flowing Curves for the Tokyo Legacy Half Marathon 2025
Oct 10, 2025 3:00 JST
|
|
|
Genequest and Fujitsu uncover new insights into genetics-lifestyle relationships through high-speed, reliable causal AI from Fujitsu Kozuchi
Oct 9, 2025 0:55 JST
|
|
|
Sharp Launches A3 MFPs (BP Series)
Oct 9, 2025 0:50 JST
|
|
|
Mitsubishi Shipbuilding Holds Christening and Launch Ceremony in Shimonoseki for Large Car Ferry HAMANASU
Oct 9, 2025 0:42 JST
|
|
|
GSK Unveils Fast-Tracked IBP Transformation with OMP at Gartner Supply Chain Planning Summit
Oct 9, 2025 23:00 HKT/SGT
|
|
|
Honda Celebrates 30th Anniversary of CR-V
Oct 9, 2025 23:54 JST
|
|
|
DASSAI MOON Project, the World's First Test Brewing of Sake in Space
Oct 9, 2025 23:23 JST
|
|
|
Focus Graphite Announces Marketing and Investor Awareness Campaign
Oct 9, 2025 21:29 HKT/SGT
|
|
|
All-New Destinator Wins Gold Award at VMARK Vietnam Design Award 2025
Oct 9, 2025 22:17 JST
|
|
|
Laser Digital Partners with Solidus Labs to Advance Crypto-Native Market Surveillance
Oct 9, 2025 21:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
